SEARCH:   Advanced

Blood, 15 March 2006, Vol. 107, No. 6, pp. 2525-2530. Prepublished online as a Blood First Edition Paper on November 29, 2005; DOI 10.1182/blood-2005-06-2552. This Article Full Text (PDF) All Versions of this Article: 2005-06-2552v1 107/6/2525    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Corazza, F. Articles by Sariban, E. Search for Related Content PubMed PubMed Citation Articles by Corazza, F. Articles by Sariban, E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 28, 2005 Accepted November 7, 2005 Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia Francis Corazza*, Christophe Hermans, Stephanie D'Hondt, Alina Ferster, Alain Kentos, Yves Benoit, and Eric Sariban Laboratory of Hematology, Brugmann University Hospital, Brussels, Belgium Hematology-Oncology Unit, Hopital Universitaire des Enfants, Brussels, Belgium Hematology Department, Erasme University Hospital, Brussels, Belgium Pediatric Oncology Department, Universitaire Ziekenhuis, Gent, Belgium * Corresponding author; email: francis.corazza{at}ulb.ac.be. Thrombopoietin (TPO), the major growth factor for cells of the megakaryocytic lineage is removed from circulation by binding to c-mpl receptors present on platelets and megakaryocytes. Investigating patients with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML) and using TPO-induced c-fos protein upregulation as a marker of c-mpl functionality, c-mpl-presenting blast cells were observed in 62% ALL (37/60) but non-functional (0/28) and in 56% AML (23/39), functional in 43% (12/28). Adequate increase in serum TPO level in response to thrombocytopenia was seen in ALL and in c-mpl deficient AML. In contrast, in c-mpl proficient AML, TPO level was found to be inappropriately low but increased to expected values during induction chemotherapy as blasts disappeared. In vitro significant TPO-associated blast cells proliferation or decreased apoptosis was observed only in c-mpl+ AML as compared to ALL or c-mpl- AML and was highly correlated with in vivo low TPO levels (p< 0.001). These data suggest that in AML, inadequate low TPO level is secondary to TPO clearing by functional c-mpl receptor myeloid blast cells and that TPO may serve as an in vivo myeloid leukemic growth factor in a significant number of patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Perreault and J. Burzynski Romiplostim: A novel thrombopoiesis-stimulating agent Am. J. Health Syst. Pharm., May 1, 2009; 66(9): 817 - 824. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020